Stage IV Non-small Cell Lung Cancer
166
9
14
98
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
57 trials with published results (34%)
Research Maturity
98 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.7%
31 terminated out of 166 trials
76.0%
-10.5% vs benchmark
3%
5 trials in Phase 3/4
58%
57 of 98 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 98 completed trials
Clinical Trials (166)
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
CISH Inactivated TILs in the Treatment of NSCLC
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
Patient-centered, Optimal Integration of Survivorship and Palliative Care
PALACE: Cemiplimab Trial According to ctDNA Levels
TG4010 and Nivolumab in Patients With Lung Cancer
Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer